Time will tell I guess! There is no evidence of massive improvement in cell potency, the changes have been more manufacturing tweaks (there's not much you can do to a very crude process involving cells sticking to plastic anyway). And in that vein I should correct a previous post by @LeftYahoo - the cells have not been modified by fucosylation or anything else - any significant modifications will require MSB to start again from the beginning (including Phase 1).
My considered view is that a small scale adult "study" will not trump the previous RCT's - no matter what data mining or analysis MSB has done on its adult data. I personally doubt FDA will agree to the proposed study but will insist on a proper trial. Even if I am wrong, and they authorise the study, I consider the chances of success/approval are slim indeed.
Much better to focus very limited resources on the other opportunities in the portfolio IMHO.
CEO Itescu needs to go, page-776
-
- There are more pages in this discussion • 138 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |